紫杉醇药物涂层球囊成形术治疗症状性椎动脉开口处狭窄的疗效

Paclitaxel drug-coated balloon angioplasty for patients with symptomatic vertebral artery origin stenosis

目的探讨紫杉醇药物涂层球囊(P-DCB)成形术治疗症状性椎动脉开口狭窄的安全性和有效性。方法回顾性分析2017年12月至2019年6月经P-DCB成形术治疗的43例症状性椎动脉开口处狭窄的临床资料。结果所有病人均完成介入治疗,成功率为100%。术后即刻狭窄率[(12.03±2.15)%]较术前[(86.32±10.26)%]明显降低(P<0.05)。围手术期发生动脉夹层1例,无其他并发症。随访12~16个月,平均13.5个月;症状改善43例,无变化例,症状改善率为95.3%(41/43);全部病人接受DSA或CTA随访,随访狭窄率[(16.1±3.12)%]与术后即刻无统计学差异(P>0.05);5例发生再狭窄,再狭窄率为11.6%。结论P-DCB成形术治疗椎动脉开口狭窄具有较好的临床疗效。

Objective To evaluate the efficacy and safety of paclitacxel drug-coated balloon(P-DCB)angioplasty for the patients with symptomatic vertebral artery origin stenosis(VARS).Methods The clinical data of 43 consecutive patients with symptomatic VARS who underwent P-DCB angioplasty from December 2017 to June 2019 were analyzed retrospectively.Results All the procedures were completed successfully,and the success rate was 100%.The immediate postoperative stenosis rate[(12.03±2.15)%]was significantly lower than that[(86.32±10.26)%]before the operation(P<0.05).Arterial dissection occurred in 1 patient during the perioperative period.The follow-up ranged from 12 months to 16 months,with an average of 13.5 months.The symptomatic improvement rate was 95.3%(41/43).There was no statistical difference between the follow-up stenosis rate[(16.1±3.12)%]and the immediate postoperative stenosis rate(P>0.05).Restenosis occurred in 5 patients and the restenosis rate was 11.6%(5/43).Conclusion P-DCB angioplasty is a safe and good method for treatment of the patients with symptomatic VARS.